Alamar Biosciences, Inc. Common Stock (ALMR)vsAstraZeneca PLC (AZN)
ALMR
Alamar Biosciences, Inc. Common Stock
$27.89
+0.43%
HEALTHCARE · Cap: $2.01B
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 61009% more annual revenue ($61.37B vs $100.42M). AZN leads profitability with a 17.0% profit margin vs -49.4%. AZN earns a higher WallStSmart Score of 60/100 (C+).
ALMR
Avoid28
out of 100
Grade: F
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ALMR.
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 82.1% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of -33.6% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ALMR
The strongest argument for ALMR centers on Revenue Growth, Debt/Equity. Revenue growth of 82.1% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bear Case : ALMR
The primary concerns for ALMR are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ALMR profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
ALMR is growing revenue faster at 82.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 28/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alamar Biosciences, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases utilizing its proprietary technology platform. The company is recognized for its ability to provide rapid and precise testing, which enhances clinical decision-making and improves patient outcomes. With a strong commitment to ongoing research and development, Alamar is well-positioned to address pressing medical needs, making it an appealing investment opportunity for institutional investors looking to capitalize on growth within the expanding diagnostics market.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?